North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
FITC Mouse Anti-Human CD27 L128 RUO (GMP)

FITC Mouse Anti-Human CD27 

Clone  L128   (RUO (GMP))

  • Concentration 0.8 μg/mL
  • Vol. Per Test 20 μL
  • Isotype Mouse BALB/c IgG1
  • Reactivity Human (QC Testing) 
  • Application Flow cytometry (Routinely Tested) 
  • Immunogen Human Activated Peripheral Blood Cells
  • Workshop No. VI T6T037
  • Entrez Gene ID 939 
  • Storage Buffer Phosphate buffered saline with gelatin and 0.1% sodium azide.
  • Regulatory Status RUO (GMP)
Product Details Recommended Assay References

Description

The CD27 antibody, clone L128, is derived from hybridization of mouse Sp2/0 cells with spleen cells from BALB/c mice immunized with activated peripheral blood lymphocytes.

The CD27 antibody recognizes a 110–120-kilodalton (kDa) disulfide-linked homodimer comprised of two 55-kDa polypeptide chains. The CD27 antigen is a lymphocyte-specific member of the tumor necrosis factor receptor (TNFR) super family, which also includes nerve growth factor receptor, CD30, CD40, CD95 (Fas), CD120a, CD120b, CD134 (OX 40), and CD137. The CD27 antigen is also known as S152, T14, TNFRSF7, and Tp55.

Format
  • Format FITC
  • Excitation Source Blue 488 nm
  • Excitation Max 494 nm
  • Emission Max 520 nm

FITC, fluorescein isothiocyanate, is a fluorochrome with a molecular weight of 389 Da. FITC is sensitive to pH changes and photobleaching. Due to nearly identical excitation and emission properties but different spillover characteristics, FITC and Alexa Fluor® 488 cannot be used simultaneously. FITC is relatively dim and should be reserved for highly expressed markers whenever possible.

Other Formats →

Resources & Tools
 Spectrum Viewer  Panel Designer  Spectrum Viewer  Download TDS  Regulatory Document Website
Preparation and Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.


  1. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.

  2. Akiba H, Nakano H, Nishinaka S, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem. 1998;273:13353-13358.

  3. Appay V, Papagno L, Spina CA, et al. Dynamics of T cell responses in HIV infection. J Immunol. 2002;168:3660-3666.

  4. Baars PA, Maurice MM, Rep M, Hooibrink B, van Lier RA. Heterogeneity of the circulating human CD4+ T cell population: further evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells. J Immunol. 1995;154:17-25.

  5. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol 1994;152:1756-1761.

  6. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T-cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol. 1991;147:3165-3169.

  7. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  8. de Jong R, Brouwer M, Hooibrink B, van der Pouw-Kraan T, Miedema F, van Lier RA. The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol. 1992;22:993-999.

  9. de Jong R, Loenen WA, Brouwer M, et al. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J Immunol. 1991;146:2488-2494.

  10. Elrefaei M, El-Sheikh N, Kamal K, Cao H. HCV-specific CD27-CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection. Immunology. 2003;110:513-518.

  11. Elson LH, Shaw S, Van Lier RA, Nutman TB. T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for Th2 cells. Int Immunol. 1994;6:1003-1009.

  12. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.

  13. He L, Fox MH. Comparison of flow cytometry and western blotting to measure Hsp70. Cytometry. 1996;25:280-286.

  14. Hintzen RQ, de Jong R, Hack CE, et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol. 1991;147:29-35.

  15. Hintzen RQ, De Jong R, Lens SM, Brouwer M, Baars P, Van Lier RA. Regulation of CD27 expression on subsets of mature T lymphocytes. J Immunol. 1993;151:2426-2435.

  16. Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, Van Lier RA. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994;152:1762-1773.

  17. Kobata T, Agematsu K, Kameoka J, Schlossman SF, Morimoto C. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol. 1994;153:5422-5432.

  18. Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci U S A. 1995;92:11249-11253.

  19. Kobata T, Morimoto C. CD27 Workshop Panel Report. In: Kishimoto T, Kikutani H, von dem Borne AEGK, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing, Inc.; 1997:67-69.

  20. Kuijpers TW, Vossen MT, Gent M-R, et al. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol. 2003;170:4342-4348.

  21. Malbran A, Belmonte L, Ruibal-Ares B, et al. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. Blood. 2004;103:1625-1631.

  22. Martorell J, Rojo I, Vilella R, Martinez-Caceres E, Vives J. CD27 induction on thymocytes. J Immunol. 1990;145:1356-1363

  23. Maurer D, Fischer G, Fae I, et al. IgM and IgG but not cytokine secretion is restricted to the CD27+ Blymphocyte subset. J Immunol. 1992;148:3700-3705.

  24. Morimoto C. Cluster report: CD27. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:356-357.

  25. Reiter C. Cluster report: CD7. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:341-342.

  26. Sugita K, Dasgupta J, Mojima Y, Agematsu K, Schlossman S, Morimoto C. Protein kinase A-mediated phosphorylation of the T-cell surface antigen CD27. Immunology. 1993;80:217-221.

  27. Sugita K, Robertson MJ, Torimoto Y, Ritz J, Schlossman SF, Morimoto C. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J Immunol. 1992;149:1199-1203.

  28. Walker EB, Haley D, Miller W, et al. gp100209-2M peptide immunization of human lymphocyte antigen A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res. 2004;10:668-680.

  29. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23-68.

  30. Zola H, Swart B, Nicholson I, Voss E. Leukocyte and Stromal Cell Molecules: The CD Markers. Hoboken, NJ: John Wiley & Sons, Inc.; 2007

340424 Rev.
Instruments
Reagents
Applications
Sales & Support
BD BioSciences